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Abstract A pair of 35 kDa polypeptides (TAO1/TAO2) are
expressed in more than 90% of all primary lung adenocarcino-
mas but not in other major malignancies. Mass spectrometry of
tryptic peptides showed that TAO1/TAO2 is identical to napsin
A, a recently described member of the aspartic proteinase family.
The site of processing of pronapsin A to the mature form was
located. Napsin expression was detected in human lung
adenocarcinoma tumors, compatible with the marker nature of
TAO1/TAO2 in the diagnosis of primary lung adenocarcinoma.
This is important since identification of markers which can
distinguish primary lung adenocarcinomas from distant metas-
tases is desirable. Northern blot analysis showed expression of
napsin also in normal lung and kidney tissue, and in situ
hybridization showed expression in type II alveolar cells of the
lung. This protease is concluded to have a specific functional role
in the normal alveolar epithelium and is a candidate protease for
the proteolytic processing of surfactant precursors.
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1. Introduction
Lung cancer is the most frequently diagnosed major cancer
in the world and the most common cause of cancer death [1].
The trend is now a decline for most histological types of lung
cancer among males, whereas the incidence does not decrease
among women [1]. Non-small cell lung cancer (NSCLC) ac-
counts for 70^80% of all lung cancers and includes squamous
cell carcinoma (epidermoid carcinoma), adenocarcinoma and
large cell carcinoma [2]. Adenocarcinoma develops from type
II pneumocytes and from bronchiolar non-ciliated secretory
cells (Clara cells) [3,4]. The lung is also a common site for
metastasis from tumors growing at other sites in the body.
There is a need for markers which can distinguish primary
lung adenocarcinomas from distant metastases to the lung,
since treatment protocols di¡er between primary lung cancer
and metastatic disease. Some such markers have been de-
scribed, including surfactant proteins [3], TTF-1 (thyroid tran-
scription factor-1) [5] and members of the mucin family of
glycoproteins [6]. However, better markers are needed to dis-
tinguish between primary and metastatic lung adenocarcino-
ma.
A pair of polypeptide markers for lung adenocarcinoma has
been described using two-dimensional gel electrophoresis (2-
DE) [7,8]. These 35 kDa markers, TAO1/TAO2, have slightly
di¡erent isoelectric points. Examination of 57 di¡erent pri-
mary lung carcinomas using 2-DE showed that 52 (91%) ex-
pressed TAO2 [8]. We have determined the amino acid se-
quence of tryptic peptides derived from TAO2 and report
that these polypeptides are identical to a recently described
[9] aspartic protease, napsin A, uniquely expressed in lung and
kidney cells. In situ hybridization detected napsin A in type II
pneumocytes in normal lung tissues, and napsin A expression
was found in lung adenocarcinomas. The expression of napsin
A in de¢ned cells in the normal lung epithelium suggests an
important functional role for this protease which may involve
the proteolytic processing of lung surfactant protein precur-
sors.
2. Materials and methods
2.1. Two-dimensional electrophoresis (2-DE) and mass spectrometric
analysis of TAO1 and TAO2
Lung adenocarcinomas were obtained shortly after resection, and
the cells were isolated [10], solubilized and subjected to 2-DE [11]. The
TAO1 and TAO2 spots were excised from Coomassie brilliant blue
stained gels, destained, and digested with trypsin (1 pmol/Wl) (Prom-
ega). The resulting fragments were analyzed by MALDI-TOF, and
sequenced by capillary HPLC-tandem mass spectrometry using an ion
trap instrument (Finnigan MAT LCQ) equipped with a micro-electro-
spray ionization source [12].
2.2. EST clones and human fetal lung cDNA library screening
Four EST clones (W19120, T54068, R11458, AA359075) that con-
tained the sequences corresponding to the TAO1/2 peptide sequences
were obtained from the American Type Culture Collection. In order
to identify a full length clone, a human fetal lung cDNA library
(Clontech) was screened with a 565 bp probe from the W19120 clone
or a 517 bp probe from the T54068 clone puri¢ed after polymerase
chain reaction (PCR) and labeled with [K-32P]-dCTP (NEN) using a
random priming kit (Stratagene) [13]. Three positive clones were se-
lected from the secondary screening using W19120, and DNA se-
quencing indicated that only one was a full length clone (W3). The
coding region of this clone was sequenced for both strands using
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overlapping primers. The probe from T54068 detected several positive
candidates which were selected from the secondary screening. Three of
the candidate clones were found to have sequences identical to those
of W19120. None matched the sequence of T54068, R11458 or
AA359075.
2.3. Northern blotting
Human multiple tissue Northern blots and a human RNA master
blot were obtained from Clontech. The cDNA probe was ampli¢ed
by PCR using a cloned cDNA prepared from the fetal lung
cDNA library with a sense primer, 5P-TCAAGCGCTATGTCTCC-
ACCACCGCTGCT-3P (nucleotide 1^20, napsin A), and an antisense
primer, 5P-CAGACTGAATTCTCACCCGGGGAACTGCGCCTG-
3P (nucleotide 1243^1263), and labeled with [K-32P]-dCTP (NEN) by
random primed labeling. After a 1 h prehybridization, hybridization
was performed overnight at 42‡C, and blots were washed in 2USSC,
and 2USSC, 1% SDS, at room temperature, and 0.2USSC, 0.1%
SDS, at 42‡C for 5 min, then autoradiographed at 380‡C.
2.4. 2-DE, SDS/PAGE and immunoblotting
Rabbit polyclonal antibody speci¢c for napsin A was raised against
the napsin A sequence 64^80Cys (i.e. KPIFVPLSNYRDVQYFGC)
conjugated to keyhole limpet hemocyanin through an added carboxy-
terminal cysteine residue. Tissue samples were obtained from CHTN
(Cooperative Human Tissue Network, Philadelphia, PA, USA). Fro-
zen tissues were thawed and homogenized in ice-cold lysis bu¡er con-
taining 50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 150 mM NaCl, 1%
Triton X-100, 50 mM NaF, 10 mM sodium pyrophosphate, 1 mM
sodium orthovanadate, 1 mM sodium molybdate, 10 Wg/ml aprotinin,
10 Wg/ml leupeptin, 5 Wg/ml pepstatin, 0.5 mM PMSF, 25 mM L-gly-
cerophosphate. Protein concentration of the supernatant was meas-
ured using the BioRad protein assay. For SDS/PAGE, 20 Wg protein
for each sample was loaded per lane on a 10% Tris-glycine polyacryl-
amide gel (Novex) and electrophoresed at 125 V for 90 min at room
temperature, while 2-DE was performed with 50 Wg protein [11]. Pro-
teins were then transferred to polyvinylidene di£uoride (PVDF) mem-
branes by electroblotting. After blocking of membranes in 5% BSA in
PBS/Tween-20 at room temperature for 1 h, napsin A was detected by
a 1 h incubation with an immunopuri¢ed rabbit polyclonal antibody
against the N-terminal napsin A peptide at 1:2000 dilution. This was
followed by incubation with an antirabbit secondary antibody conju-
gated to horseradish peroxidase at room temperature for 30 min.
Bands were visualized by Super Signal Chemiluminescent Substrate
(PIERCE) and exposed to Kodak BioMax MR ¢lm for 10^15 min.
2.5. In situ hybridization
In situ hybridization was performed on samples of formalin ¢xed,
para⁄n embedded tumor tissue. In brief, 6 Wm tumor sections were
Fig. 1. Amino acid sequence (A) and analysis (B) of human pronapsin A. The continuous sequence in A is deduced from the nucleotide se-
quence of a cDNA clone (W3). For pronapsin B the corresponding amino acid exchanges are shown below the pronapsin A sequence. The po-
sitions of the ¢ve peptides identi¢ed by mass spectrometry are boxed and the peptide used for raising antibodies (Pab-Npep) is underlined. In
B, the identi¢cation, by ion trap mass spectrometry, of the sequence of the amino-terminal peptide of the mature form is shown (top part)
with the observed m/z values of the fragmentation products underlined as deduced from the fragmentation mass spectrum of the same peptide
(bottom part). Segments of the pro¢le which were expanded in the direction of the y-axis by 2.8 or 3.8U are indicated and both the b and y
ions are clearly identi¢able.
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depara⁄nized with xylene, treated with proteinase K (1 Wg/ml, 30 min,
37‡C), transferred to 0.1 M triethanolamine bu¡er (5 min), and
treated with triethanolamine containing 0.25% acetic anhydride for
10 min. Sections were washed in 2USSC, dehydrated, and allowed
to air-dry. After overnight hybridization (2USSC, 50% formamide,
10% dextran sulphate, 55‡C) with a 35S-labeled RNA probe
(1.16U105 cpm/Wl), sections were washed (the most stringent step
being 0.1USSC, 15 min at 60‡C) and RNAse A treated (20 Wg/ml,
30 min, 37‡C). Finally, the slides were dehydrated, air-dried, dipped in
Kodak NTB emulsion, exposed for 6 or 19 days, and were developed
and hematoxylin-eosin stained. The probes were made using T3 (anti-
sense) and T7 (sense) RNA polymerase (Promega) from a pCMS-
EGFP vector (Clontech) containing an Nhe1/EcoR1 napsin A insert.
3. Results
3.1. Identi¢cation of TAO1 and TAO2 and cloning of the
corresponding cDNA
Viable tumor cells were prepared from freshly excised pri-
mary tumors as described [10]. Cell lysates were subjected to
two-dimensional gel electrophoresis using immobilized pH
gradient (IPG) electrophoresis in the ¢rst dimension. After
staining the gels with Coomassie brilliant blue, the protein
spots corresponding to TAO1 and TAO2 [7,8] were excised
and pooled for in-gel digestion. Mass spectrometry of frag-
ments revealed several peptides common to TAO1 and TAO2
tryptic digests, and ¢ve were subjected to collision-induced
dissociation (CID). Interpretation of these spectra (Fig. 1B)
yielded peptide sequences which were used to search the hu-
man EST (expressed sequence tags) GenBank database. Four
EST clones were identi¢ed that contained TAO1/2 sequences.
The ¢rst clone, of 495 bp (W19120), had the correct sequence
of two out of the ¢ve peptides; however, the last three clones
(T54068, R11458, AA359075) were overlapping to each other
and contained all the peptide sequences but with several ami-
no acid exchanges (Fig. 1A) and lacked an in-frame stop
Fig. 2. Expression of napsin mRNA in human tissues and cancer cell lines. A: Northern blot analysis showing strong signals in lung and kid-
ney tissues and weak signals in spleen, PBL, HL60 and Raji. Marker fragments of 2.37 and 1.35 kb migrated as indicated. B: Dot blot analysis
of di¡erentiated and fetal human tissues. Napsin mRNA is expressed predominantly in adult lung and kidney and in fetal lung.
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codon. Screening a human fetal lung cDNA library yielded a
full length cDNA clone, which had a sequence identical to the
recently described aspartic protease napsin A [9]. Interest-
ingly, we were unable to identify peptides in our tryptic digest,
or a clone in the lung cDNA library, corresponding to a
second gene (napsin B), which apparently is transcribed ex-
clusively in cells of the immune system [9].
3.2. Expression of napsin mRNA
The distribution of napsin mRNA was examined by North-
ern blot (Fig. 2A) and dot blot (Fig. 2B) analyses using a full
length cDNA probe. The probe annealed to a 1.6 kb tran-
script which was highly abundant in lung, and also expressed
in the kidney, spleen and peripheral blood leukocytes (Fig.
2A). In fetal tissue, again the most abundant expression was
detected in lung, with low levels also in fetal kidney (Fig. 2B).
No detectable amount of the mRNA was found in other tis-
sues. Napsin mRNA expression was detected in HL60 pro-
myelocytic leukemia and in Raji Burkitt lymphoma cells, but
not in the A549 lung adenocarcinoma cell line. None of these
cell lines express the TAO1/2 (napsin A) protein. It appears
likely that cells derived from the immune system express only
the napsin B message which di¡ers from napsin A in the
coding sequence, and probably in the sequence of the 5P-£ank-
ing region in order to achieve such speci¢c cell type expres-
sion.
3.3. Expression of TAO1/2 (napsin) protein
In order to analyze the protein expression, we raised a
rabbit polyclonal antibody against the amino-terminal peptide
of the mature form (PAb-Npep) (Fig. 1A). Western immuno-
blotting was performed, initially after one-dimensional elec-
trophoresis (1-DE) SDS/PAGE. Control experiments showed
that the antibody recognized a thioredoxin-napsin A fusion
protein expressed in Escherichia coli. The results of the West-
ern analyses showed that the immunopuri¢ed antibody de-
tected TAO1/2 (napsin A) in six/six normal lung samples
and two/four normal kidney samples, but not in breast or
colon tissues. In cancerous samples, three/three lung and
one/six kidney tissues expressed the TAO1/2 (napsin A) pro-
tein, whereas three breast, one colon, four lymphomas and
seven lung cancer cell lines did not express the protein. Im-
munoblotting with the immunopuri¢ed antibody was also car-
ried out following 2-DE. Both lung and kidney tissues are
positive for 35 kDa TAO1/2 spots (Fig. 3).
3.4. Napsin expression in normal lung tissue and in
adenocarcinomas
Napsin expression was studied in tissue sections using in
situ hybridization. Both sense and antisense probes were syn-
thesized and hybridized to all sections. Hybridization with
sense probes resulted in a di¡use background, and did not
localize speci¢cally to cells. As shown in Fig. 4A and B,
only some cells of the normal alveolar epithelium expressed
napsin (indicated by arrows). These cells showed the charac-
teristics of type II pneumocytes. Three intermediately or in-
termediately/poorly di¡erentiated lung adenocarcinomas, and
one highly di¡erentiated lung adenocarcinoma, showed strong
napsin mRNA expression (Table 1). In contrast, speci¢c hy-
bridization was not observed to two poorly di¡erentiated tu-
mors/areas. Napsin mRNA expression in a highly di¡erenti-
ated area of tumor 94-9235 and in the intermediately
di¡erentiated tumor 94-9979 is shown in Fig. 4C and D.
4. Discussion
We have identi¢ed and sequenced ¢ve peptides derived
from the TA01/2 spots. Using these sequences as probes, we
established that the TA01/2 protein is napsin A and that a
mature 35 kDa form, lacking a propeptide is prevalently ex-
pressed both in normal and cancerous cells. Napsin A was
described [9] as a new member of the aspartic protease family
during the time that this work was in progress. The cDNA
sequences of two closely related genes were reported, pronap-
sin A predominantly expressed in lung and kidney, and pro-
napsin B exclusively expressed in cells derived from the im-
mune system, but lacking an in-frame stop codon and
containing several amino acid exchanges [9]. We completely
agree on those results. We also provide detailed analysis at the
protein level. Processing of pronapsin A to the mature form is
now concluded to occur between Asp-63 and Lys-64, since
cleavage to generate peptide KPIFVPLSNYR could not be
the result of trypsin digestion. Napsin A showed three to
four isoelectric forms in 2-DE. Two forms with a slightly
higher molecular weight were also found in some samples.
Three potential N-glycosylation sites are predicted in the ma-
ture enzyme and could be responsible for such heterogeneity.
Our results obtained from in situ hybridization establish
that napsin mRNA is highly expressed in normal type II
Fig. 3. 2-DE pro¢les of a panel of normal and tumor cell extracts
from lung and kidney. Polypeptides corresponding to TA01 and
TA02 were revealed by immunoblotting with an immunopuri¢ed
antibody to a synthetic amino-terminal peptide. No other spots
were observed in the 2-DE gels.
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lung pneumocytes. Type II pneumocytes secrete surfactant in
the form of tubular myelin which is converted to a small
vesicular form. Both surfactant protein B and C are derived
from larger precursors [14], and an aspartic protease has been
implicated in the cleavage of pro-surfactant protein B to the
mature form [15]. The speci¢c localization of napsin A expres-
sion to type II pneumocytes raises the possibility that this
aspartic protease is napsin A.
Strong TAO1/TAO2 expression has been reported [8] in
highly di¡erentiated lung adenocarcinomas, whereas dedi¡er-
entiated tumors showed weaker expression. Nevertheless, nap-
sin A was detected by 2-DE in a high percentage (s 90%) of
clinically observed lung adenocarcinomas and may become a
useful marker in the di¡erential diagnosis between primary
and metastatic lung adenocarcinoma. Our in situ hybridiza-
tion data demonstrated napsin expression in adenocarcinoma
tumor cells, whereas the tumor stroma was negative. Consis-
tent with the report from Hirano et al. [8], we ¢nd stronger
napsin expression in highly and intermediately di¡erentiated
adenocarcinomas than in poorly di¡erentiated adenocarcino-
mas. The analysis of the titer of napsin A in the serum could
be of use in lung cancer diagnosis, in the same manner as
analyses of the serine proteases human glandular kallikrein
2 (hK2) and prostate speci¢c antigen (PSA or hK3) are for
evaluation of prostate cancer disease progression [16]. Both
proteases are highly expressed in normal prostate tissue and in
prostate cancer.
In conclusion, we have shown high expression in speci¢c
alveolar cells of the protease napsin A. The restricted pattern
of expression makes napsin A a marker for primary lung
adenocarcinoma and a candidate protease for the cleavage
of pro-surfactant proteins.
Fig. 4. In situ hybridization using a 35S-labeled antisense napsin RNA probe. A (20U objective) and B (40U objective): normal lung tissue.
Type II alveolar cells, with large cytoplasms, show hybridization to the napsin probe (red arrows). C (20U objective): strong napsin mRNA
expression in a highly di¡erentiated area of lung adenocarcinoma 94-9235. D (20U objective): strong napsin mRNA expression in lung adeno-
carcinoma 94-9979.
Table 1
Expression of napsin mRNA in lung adenocarcinomas
Tumor Histologya Hybridization score
93-13596 intermediate/low ++
93-12807 intermediate/low (some
gland formation)
+++
94-9979 intermediate +++
94-9235 highb +++
lowb 3
94-1228 low 3
aEvaluated blindly by two independent pathologists. Tumors were
classi¢ed as showing high/intermediate/low grade of di¡erentiation.
bThis tumor contained two distinct areas showing di¡erent histolo-
gies.
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